Drug Research, Table of Contents Drug Res (Stuttg) 2021; 71(S 01): S22-S23DOI: 10.1055/a-1606-5955 Extended Abstract Therapie des hepatozellulären Karzinoms – eine neue Dekade? Raphael Mohr , Frank Tacke Recommend Article Abstract Full Text References Literatur 1 Lee YT, Wang JJ, Luu M. et al. The mortality and overall survival trends of primary liver cancer in the United States. J Natl Cancer Inst 2021; [Epub ahead of print] 2 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314 3 Roderburg C, Ozdirik B, Wree A. et al. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020; 7: HEP20 4 Mohr R, Jost-Brinkmann F, Ozdirik B. et al. Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma. Front Immunol 2021; 12: 652172 5 Finn RS, Qin S, Ikeda M. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894-1905 6 Pfister D, Nunez NG, Pinyol R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021; 592: 450-456 7 Vogel A, Martinelli E. clinicalguidelines@esmo.org EGCEa, Committee EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol 2021; 32: 801-805 8 Greten TF, Mauda-Havakuk M, Heinrich B. et al. Combined locoregional-immunotherapy for liver cancer. J Hepatol 2019; 70: 999-1007 9 Forner A, Da Fonseca LG, Diaz-Gonzalez A. et al. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019; 1: 17-29 10 Peiseler M, Tacke F. Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma. Cancers (Basel) 2021; 13: 730
